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Accumulation of the microtubule associated protein tau occurs in several
neurodegenerative diseases including Alzheimer’s disease (AD). The tau protein is
intrinsically disordered, giving it unique structural properties that can be dynamically
altered by post-translational modifications such as phosphorylation and cleavage.
Over the last decade, technological advances in nuclear magnetic resonance (NMR)
spectroscopy and structural modeling have permitted more in-depth insights into
the nature of tau. These studies have helped elucidate how metamorphism of tau
makes it ideally suited for dynamic microtubule regulation, but how it also facilitates
tau self-assembly, oligomerization, and neurotoxicity. This review will focus on how the
distinct structure of tau governs its function, accumulation, and toxicity as well as how
other cellular factors such as molecular chaperones control these processes.
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INTRODUCTION
The microtubule-associated protein tau accumulates in a number of neurodegenerative diseases
termed tauopathies, including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP),
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and several
others. Many of these diseases are caused by missense mutations in the MAPT gene coding for
tau, while several others are caused by environmental factors: chronic traumatic encephalopathy
(CTE) is a sequelae of traumatic brain injury (TBI), postencephalitic parkinsonism (PEP) results
from infection, while the cause of age-related AD is unknown. The sheer diversity of the factors
that ultimately lead to tauopathy and neurodegeneration is quite remarkable and suggestive of a
broad neurological reaction in response to a variety of insults. Because the disordered structure
of tau lends itself to heavy post-translational modifications, signaling events caused by these
environmental factors can have a multitude of effects on tau structural dynamics.
Tau aggregates into ß-sheet fibrils in tauopathies, leading to the formation of neurofibrillary
tangles (NFTs) and subsequent cell death. Although precisely what triggers tau assembly
into these ß-sheet structures in the brain is unclear, it is known that a number of post-
translational modifications can regulate this process, including phosphorylation, acetylation,
cleavage, ubiquitination, and misfolding. This mini-review will reveal what has been recently
discovered about tau structure and how distinct cellular mechanisms such as molecular chaperones
can control tau folding to promote or block its toxic assembly [for more comprehensive reviews on
tau structure and pathology, we direct readers to Kolarova et al. (2012) and Wang and Mandelkow
(2016)].
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OVERVIEW OF TAU STRUCTURE
Tau is an intrinsically disordered protein with a strong propensity
for self-aggregation into ß-sheet structures which compose the
core of NFTs. Several factors can enhance the propensity of
tau to aggregate, including mutations in the MAPT gene and
post-translational modifications such as phosphorylation and
acetylation (Goedert et al., 1988; Hutton et al., 1998; Spillantini
et al., 1998; Von Bergen et al., 2001; Augustinack et al., 2002;
Cohen et al., 2011;Mandelkow andMandelkow, 2012; Cook et al.,
2014; Min et al., 2015). Another post-translational modification
to tau, ubiquitination, has been shown to be required for tau
ß-sheet assembly in vivo; but when ubiquitination was blocked,
soluble tau intermediates, typically termed oligomers, developed
in the brain that were highly toxic (Dickey et al., 2006b). This
idea of soluble tau oligomers being the major toxic species in the
brain has gained recent support because of key studies that have
emerged over the past decade (Santacruz et al., 2005; Oddo et al.,
2006; Spires et al., 2006; O’leary et al., 2010). Using tools that have
been developed to specifically investigate oligomeric tau species,
it has been demonstrated that these structures were responsible
for much of the neurotoxicity due to tau accumulation (Lasagna-
Reeves et al., 2011; Blair et al., 2013). Moreover, several studies
have shown that reducing soluble tau mitigates neuronal loss
and functional deficits in tau transgenic mice, despite the lack of
change in ß-sheet aggregates (Santacruz et al., 2005; Oddo et al.,
2006; Spires et al., 2006; O’leary et al., 2010). Thus, it is clear
that elucidating the processes governing tau oligomerization
and aggregation is critical for not only understanding tau
pathogenesis but also for developing tau-based therapeutics.
The structure of tau has been extensively analyzed in an
effort to gain insight into the mechanisms of its aggregation and
toxicity. Initial approaches using fluorescence resonance energy
transfer (FRET) theorized a “paper clip” model of tau wherein
the N and C termini transiently fold onto the microtubule-
binding repeat domains as well as each other (Jeganathan et al.,
2006). The tau protein contains either 3 or 4 microtubule-
binding domain repeats (3R or 4R) which have been shown to
be essential for both the ability of tau to bind to microtubules
and its assembly into paired helical filaments (PHFs). Specifically,
stretches of amino acid residues within these repeat domains,
which include the hexapeptide motifs VQIIYK and VQIVYK,
are capable of serving as seeds for aggregation (Von Bergen
et al., 2001; Mukrasch et al., 2005). In fact, these motifs are
uniquely critical for the intermolecular contact between tau
molecules which gives rise to initial oligomer formation and
eventual self-aggregation (Peterson et al., 2008). Moreover, the
hexapeptide motifs have intramolecular contacts with proline-
rich regions on tau, suggesting proline-directed phosphorylation
may alter tau structure, affecting its aggregation propensity
(Mukrasch et al., 2009). More recent work has corroborated
this idea, demonstrating that intramolecular interactions in
the repeat domains promote aggregation, whereas the more
unstructured N terminus folds longer stretches which prevent
aggregation (Wegmann et al., 2011). Disulfide cross-linking
of tau can also play a substantial role in its aggregation
propensity: 3R tau contains only one cysteine, oxidation of
which permits cross-linking, oligomerization, and aggregation.
Conversely, 4R tau contains two cysteines which readily form
intramolecular contacts and can suppress cross-linking and
aggregation (Schweers et al., 1995; Barghorn and Mandelkow,
2002). The consequences of these intra- and intermolecular tau
interactions in vivo likely depend on a multitude of factors such
as phosphorylation state, proteostatic burden, and binding to
microtubules.
TAU-MICROTUBULE INTERACTIONS
INFLUENCE TAU STRUCTURE, ASSEMBLY,
AND TOXICITY
It is likely not a coincidence that the regions within tau necessary
for binding to microtubules are also important for ß-sheet
assembly and aggregation. The first discovered function of tau
was its ability to promote microtubule assembly (Weingarten
et al., 1975) and subsequent studies have only reinforced
these findings, showing that tau stabilizes microtubules with
a high affinity through interactions within its microtubule-
binding repeats (Goode et al., 1997; Sillen et al., 2007). The
mechanism by which tau stabilizes microtubules was only
very recently established using nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry. Zweckstetter and
colleagues revealed that tau binds to microtubules at the interface
between tubulin heterodimers, using small groups of residues
that have previously been shown to be critical for tau ß-sheet
assembly and aggregation (Kadavath et al., 2015). The authors
highlight the implication that competition may arise between
the physiological interaction of tau with microtubules and
tau misfolding and aggregation. Phosphorylation of tau can
prevent its binding to microtubules, which could potentially
give rise to a feed-forward loop under pathological conditions.
In this scenario, hyperphosphorylation of tau, characterized
by abnormal tau conformations, and self-assembly into PHFs,
causes gain of toxicity as well as loss of function if it is
unable to stabilize microtubules. Thus, loss of axonal stability




As discussed above, tau structure and conformation can be
altered by several primary post-translational factors, but the
best characterized of these are phosphorylation and proteolytic
cleavage. Tau phosphorylation has a dramatic effect on the
structure and function of tau, potentially obscuring the
microtubule binding sites within the repeat domains. However,
not all phospho-epitopes behave the same. For example, when
tau is phosphorylated at the AT8 (S202/T205) and AT180
(T231) sites, it loses the ability to drive microtubule assembly,
but can still associate with preformed microtubules (Amniai
et al., 2009). In contrast, MARK-dependent phosphorylation
of tau at S262 induces conformational changes around this
phosphorylation site, altering tau structure and attenuating
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microtubule binding (Fischer et al., 2009). A recent investigation
of tau phosphorylated at T231 revealed that this residue can
selectively form a salt bridge with R230, which competes with the
bridge necessary for tau-microtubule interaction (Schwalbe et al.,
2015). Tau phosphorylation not only affects local conformations
but has also been shown to weaken the transient long-range
interactions common to intrinsically disordered proteins (Bibow
et al., 2011; Sibille et al., 2012), potentially making tau more
susceptible to aggregation. These studies and others have made
it clear that phosphorylation of tau not only influences the
aggregation potential of the protein, but can also have more
immediate consequences on microtubule binding and folding.
Tau can also be modified by proteolytic cleavage events,
altering its structure, functional capacity, and self-association.
Tau can be cleaved by caspase-3, most notably at D421, or by
the calcium-dependent protease calpain, which leads to a 17 kDa
tau fragment (Hanger and Wray, 2010). Cleavage by either of
these proteases produces truncated tau forms which are more
neurotoxic than full-length tau (Chung et al., 2001; Park and
Ferreira, 2005). Cleaved tau has been found in the brains of
individuals with AD and other tauopathies, indicating it may
play a role in disease pathogenesis (García-Sierra et al., 2008).
Although most cleaved tau species that have been identified
are C-terminal truncations, a recent report showed that an
N-terminal truncation at Q124, identified from human brains via
proteomics, actually enhanced microtubule stability (Derisbourg
et al., 2015).
Evidence suggests that tau phosphorylationmay also influence
cleavage of tau; phosphorylation at S422 is commonly observed in
tauopathy brains and has been shown to inhibit caspase cleavage
of tau (Rissman et al., 2004; Guillozet-Bongaarts et al., 2006).
Furthermore, tau phosphorylation and cleavage differentially
affect the ability of tau to interact with microtubules (Drewes
et al., 1997; Ding et al., 2006), suggesting tau may adopt
an alternative structure that promotes aggregation following
cleavage. It was also recently discovered that tau can be cleaved
by asparagine endopeptidase, a lysosomal cysteine protease,
which (1) abrogates the ability of tau to stabilize microtubules,
(2) induces aggregation, and (3) enhances neurodegeneration
(Zhang et al., 2014). Collectively, these studies suggest that
post-translational modifications such as phosphorylation and
cleavage can affect the ability of tau to interact with microtubules
and make it more susceptible to self-assembly and aggregation.
Further work may begin to develop a clearer picture of how the
interplay between these modifications influences the propensity
of tau to form ß-sheet structures and eventual irreversible
aggregates. Other factors such as molecular chaperones also play
an important role in determining tau fate both in concert with
and independent of post-translational modifications.
CHAPERONES CONTROL TAU
STRUCTURE AND ASSEMBLY
Molecular chaperones such as Hsp70 and Hsp90 have been long
recognized as vital mediators of protein folding and structure
(Young et al., 2004). These proteins help maintain proteostasis
by attempting to refold misfolded proteins or shuttling them
to the proteasome if refolding is unsuccessful. A seminal paper
by Hu and colleagues showed that Hsp70 and Hsp90 can each
directly interact with tau, promoting tau-microtubule binding
while decreasing tau phosphorylation and aggregation (Dou
et al., 2003). Inhibition of Hsp70 or Hsp90 with siRNA or small
molecules reduces intracellular tau levels in cells and the brain
(Dickey et al., 2005, 2006a, 2007; Jinwal et al., 2009). The heat
shock response typically produced by this inhibition increases
levels of Hsp72, an inducible Hsp70 isoform, leading to enhanced
tau turnover (Dickey et al., 2006a). In fact, it is known that Hsp72
and Hsc70, the predominant, constitutively active isoform of the
Hsp70 family, have opposing effects on tau clearance, with Hsc70
preserving tau in the cell and Hsp72 promoting tau degradation
(Jinwal et al., 2013).
Tau phosphorylation seems to be an important determinant
of chaperone activity. The carboxyl terminus of the Hsc70-
interacting protein (CHIP) is a major co-chaperone of
Hsp90 and Hsc70. Tau phosphorylation is required for the
Hsc70-CHIP complex to shuttle tau to the proteasome for
ubiquitination, an event that mitigates cell death induced by
tau hyperphosphorylation (Shimura et al., 2004). Similarly, the
Hsp90-CHIP complex selectively degrades phosphorylated tau
species (Dickey et al., 2007). However, these processes appear
to be phospho-epitope specific; although tau phosphorylated at
S202/T205 and S396/S404 could be degraded by Hsp induction,
tau phosphorylated at S262/S356 was not affected (Dickey et al.,
2006a). Interestingly, deletion of CHIP promotes accumulation
of phospho-tau without promoting its aggregation (Dickey et al.,
2006b). Thus, distinct chaperones clearly recognize structural
features of tau to govern the degradation and assembly of tau.
This point is illustrated by data demonstrating that Hsp70 and
Hsp90 actually compete for binding to shared residues on tau,
leading to differential effects on tau clearance; Hsp70 stabilizes
tau levels while Hsp90 facilitates tau removal (Thompson et al.,
2012). Hsp70 and Hsp90 also have opposing effects on tau
assembly and structure in vitro. While Hsp70 prevents tau
aggregation (Patterson et al., 2011), Hsp90 stimulates it (Blair
et al., 2013). Because the dynamic chaperone landscape changes
with age and especially AD (Yoo et al., 2001; Jinwal et al., 2010;
Blair et al., 2013), it is likely that dysfunction in the ability of
Hsp70 or Hsp90 to regulate tau contributes to its misfolding and
aggregation.
Although Hsp90 is one of the more well-characterized
chaperones, it was only recently discovered how it interfaces
with a substrate (Karagoz et al., 2014). In fact, tau was the
model substrate used to determine this. Through this work,
it was found that Hsp90 interacts with a long stretch of the
tau microtubule binding repeats, essentially stretching tau out
along the N-terminal and middle domains of Hsp90 (Karagoz
et al., 2014). Although tau is intrinsically disordered, it adopts
conformations that facilitate its pathogenicity, a property that
is referred to as “meta-stability” and Hsp90 may constrain this
flexibility to some extent. But in doing so, Hsp90 can facilitate
tau ß-sheet assembly. Of course Hsp90 does not work alone
within the cell. The dynamic network of other major chaperones
and co-chaperones can influence several aspects of tau biology.
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For example, the Hsp90 co-chaperones FKBP51 and FKBP52
have opposing effects on tau assembly, oligomerization, and
aggregation (Blair et al., 2013; Giustiniani et al., 2015). Thus, a
number of cellular factors coordinate to regulate tau structure
and proteostasis; an imbalance in these factors, as occurs with
aging, could shift regulation of tau to a more pathogenic state.
CONCLUSIONS
To describe proteins like tau as intrinsically disordered may
be somewhat misleading. Perhaps proteins with unstructured
domains should rather be considered dynamically flexible,
providing a way for the cellular proteome to adapt to distinct
environments and needs. These metamorphic proteins come
with a cost however, in that some structures can promote
proteotoxicity. The factors that promote these toxic structures are
critical for our understanding of tauopathies and could each be
viable therapeutic targets. Moreover, if these transient structures
can be identified, it could usher in a new era of structure-based
drug discovery for tauopathies and other diseases associated with
metamorphic proteins. With the advent of improved methods of
3D electron microscopy and high resolution mass spectrometry,
examining these large, aggregate structures is now feasible and
will certainly yield key insights for therapeutic development in
these disorders.
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